Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.42 |
| ▸ | FNTB | P49356 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 10/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321531 | 0.81 | FNTA (0.46) | FNTAFNTBKDM4EALDH1A1RORC | |
| SCHEMBL14927293 | 0.80 | GAA (0.42) | KDM4EHSD17B10ALDH1A1RORC | |
| SCHEMBL15094045 | 0.77 | GAA (0.40) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL322378 | 0.76 | DAPK3 (0.43) | FNTAFNTBKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL2890963 | 0.74 | KDM4E (0.65) | KDM4EHSD17B10ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL31325969 | 0.74 | MAP2K3 (0.43) | FNTAFNTBKDM4EALDH1A1RORC | |
| SCHEMBL321713 | 0.73 | ALDH1A1 (0.43) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL1931167 | 0.73 | MAPT (0.51) | KDM4EALDH1A1RORC | |
| SCHEMBL18031312 | 0.71 | KMT2A (0.44) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL1931374 | 0.71 | MAPT (0.42) | FNTAFNTBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2800566-B1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2590976-B1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| EP-2800566-A1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI (FR) | 2014-11-12 | — | — | EP | disclosed |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| WO-2013102860-A1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI (FR) | 2013-07-11 | — | — | WO | disclosed |
| EP-2590976-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| WO-2012004732-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | FNTA 3161/4885FNTB 2969/4885KDM4E 728/4885 |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | CCNY, UTS2R, WNK2 | FNTA 3756/4885FNTB 3502/4885KDM4E 468/4885 |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | FNTA 3161/4885FNTB 2969/4885KDM4E 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.